Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Ranibizumab in Aggressive vs Type 1 ROP
NCT05701124Phase 3Completed
- Sponsor
- Zagazig University
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in retinopathy of prematurity (ROP), sponsored by Zagazig University. Started Nov 2020; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT05701124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701124.